BHVN

Business Context and Reporting Period

Company: Biohaven Ltd. (BHVN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments in immunology, neuroscience, and oncology. The company operates as a single segment and has no approved products generating revenue. Its portfolio includes troriluzole (SCA, OCD), taldefgrobep alfa (SMA, obesity), BHV-7000 (epilepsy, mood disorders), and various degrader and ADC platforms.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no debt obligations listed in the balance sheet liabilities.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss more than doubled from $408.2 million in 2023 to $846.4 million in 2024. This was primarily driven by a $422.6 million increase in R&D expenses.
• R&D Expense Drivers: The increase in R&D was largely due to a one-time non-cash expense of $171.9 million related to the Knopp Amendment (milestone and royalty buyback for the Kv7 platform). Additional increases were driven by advancing clinical programs (four Phase 3 starts and one Phase 2 start for BHV-7000), the acquisition of Pyramid Biosciences (BHV-1510), and increased personnel costs.
• Financing Activity: Net cash provided by financing activities increased significantly to $677.8 million, driven by two underwritten public offerings in April and October 2024 (raising approx. $517.7 million in net proceeds) and at-the-market sales.
• Liquidity Position: Total cash, cash equivalents, and marketable securities increased to $486.0 million as of December 31, 2024, up from $381.8 million in 2023.

Guidance, Outlook, and Management Commentary

• Troriluzole (SCA): In February 2025, the FDA accepted the NDA for troriluzole for the treatment of adult patients with SCA and granted priority review. A decision is expected in Q3 2025. The company is prepared to commercialize in the U.S. in 2025 if approved.
• Troriluzole (OCD): Two Phase 3 trials are ongoing. Topline data for the first study is expected in H1 2025, and the second in H2 2025.
• BHV-7000 (Epilepsy/Mood): Phase 2/3 trials in focal epilepsy and idiopathic generalized epilepsy are underway. Topline results for the first focal epilepsy study are expected in H1 2026. A Phase 2 trial for Major Depressive Disorder (MDD) is ongoing with data expected in H2 2025.
• Taldefgrobep Alfa (SMA): A Phase 3 trial in SMA did not meet its primary endpoint at Week 48 but showed clinically meaningful improvements in motor function at all timepoints. The company plans to engage the FDA in H1 2025 to discuss the registrational path forward.
• Capital Requirements: Management expects existing cash and marketable securities to fund operations for at least 12 months from the filing date. The company anticipates continuing to incur substantial operating losses for the foreseeable future and may require additional capital to pursue growth strategies.

Investor Verification Checklist

• Regulatory Milestones: Verify the FDA's decision timeline for the troriluzole SCA NDA (Priority Review) and the outcome of the FDA engagement regarding the taldefgrobep alfa SMA Phase 3 results.
• Clinical Trial Data: Monitor the release of topline data for troriluzole in OCD (H1/H2 2025) and BHV-7000 in MDD (H2 2025) and Epilepsy (H1 2026).
• Capital Adequacy: Assess the burn rate relative to the $486 million cash position to determine if additional equity dilution or debt financing will be required before 2026.
• Knopp Amendment Impact: Confirm the settlement of the 2025 Additional Consideration and any potential cash true-up payments related to the Knopp Amendment derivative liabilities.
• Commercialization Readiness: Evaluate the company's plan to build a neurological specialty sales force for troriluzole in the U.S. pending approval.